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Abstract
DNA vaccination has emerged as a promising alternative to traditional protein-based vaccines for the induction of protective immune responses. DNA vaccines offer several advantages over traditional vaccines, including increased stability, rapid and inexpensive production, and flexibility to produce vaccines for a wide variety of infectious diseases. However, the immunogenicity of DNA
vaccines delivered as naked plasmid DNA is often weak due to degradation of the DNA by nucleases and inefficient delivery to immune cells. Therefore, biomaterial-based delivery systems based on micro- and nanoparticles that encapsulate plasmid DNA represent the most promising strategy for DNA vaccine delivery. Microparticulate delivery systems allow for passive targeting to antigen
presenting cells through size exclusion and can allow for sustained presentation of DNA to cells through degradation and release
of encapsulated vaccines. In contrast, nanoparticle encapsulation leads to increased internalization, overall greater transfection efficiency, and the ability to increase uptake across mucosal surfaces. Moreover, selection of the appropriate biomaterial can lead to
increased immune stimulation and activation through triggering innate immune response receptors and target DNA to professional
antigen presenting cells. Finally, the selection of materials with the appropriate properties to achieve efficient delivery through administration routes conducive to high patient compliance and capable of generating systemic and local (i.e. mucosal) immunity can
lead to more effective humoral and cellular protective immune responses. In this review, we discuss the development of novel biomaterial-based delivery systems to enhance the delivery of DNA vaccines through various routes of administration and their implications for generating immune responses.
Keywords: DNA vaccine, biomaterials, transfection, vaccination, oral delivery

Introduction

pathogens that replicate intracellularly (e.g. viruses).3 Furthermore, traditional vaccines suffer from limited stability, dependency on ‘‘cold chain’’ storage and transport, and costly and
time-consuming production,4,5 all of which limit the potential of traditional vaccines for rapid, widespread deployment,
especially to underdeveloped regions where infectious diseases remain prevalent.
Unlike traditional protein-based vaccination, DNA vaccination involves the delivery of plasmid DNA (pDNA) encoding a pathogen-specific target antigen driven by a eukaryotic
promoter resulting in the intracellular production and subsequent immune sampling of the target antigen.6 DNA-based
vaccines are considered an attractive alternative to traditional
vaccine strategies, as they can more closely mimic live infec-

Vaccination is considered by many to be one of the most successful public health interventions of the modern era.1 The
advent and subsequent development of vaccines has led to
a dramatic increase in worldwide life expectancy and has resulted in the complete eradication of several diseases such
as smallpox and polio.2 Current vaccine methodologies are
largely protein-based and require direct administration of either dead or attenuated bacteria/viruses, recombinant proteins, or virus-like particles.3 These protein-based vaccines
often fail to generate a complete immune response and typically only generate an antibody-mediated immune response,
leading to incomplete immune protection, specifically from
1
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tions and induce both antibody and cell-mediated immune
responses.3 Furthermore, DNA vaccines eliminate the need for
cold chain storage and transportation,7 can be quickly altered
by manipulating the transgene sequence to adapt to new and
fast-emerging diseases,8 and are considered safer than traditional vaccines as the pathogen is not involved in vaccine synthesis. pDNA used in DNA vaccines can also be quickly and
easily replicated and amplified in bacteria, allowing for accelerated production time frames, and the capability of largescale production.9 In addition, DNA vaccination is applicable
to a range of viral,10 bacterial,11 and parasitic12 diseases. DNA
vaccines are also uniquely suited for anticancer and antitumor
therapies as their encoded antigen is produced intracellularly
and introduced directly onto major histocompatibility complex (MHC) class I for antigen presentation to CD8+ T cells,
which are essential effector cells for cytolytic activity.13 The
identification of the first human tumor-specific antigen recognized by CD8+ T cells introduced the possibility of cancer
immunotherapy treatments,14 and has since led to the identification of numerous tumor antigens that offer promising targets for anticancer DNA vaccination strategies.15
As with all vaccination strategies, the goal of DNA vaccination is to induce robust, protective memory immune responses, which typically require the activation and interplay
of all three arms of the immune system, including the humoral and cellular arms of adaptive immunity, as well as the
innate immune system.3 Adaptive immune responses are induced by specialized immune cells including professional
antigen presenting cells (APCs) and mediated by B- and Tlymphocyte responses. APCs, such as dendritic cells (DCs)
and macrophages, are responsible for the capture, uptake,
and processing of antigen for display on MHC Class I and II
molecules to activate and drive differentiation of CD8+ and
CD4+ T-effector cells, respectively. CD8+ T cells have cytotoxic function and serve as an effector of cellular immunity,
while CD4+ T cells activate B cells and facilitate their differentiation into high affinity, antibody-secreting plasma cells, and
memory B cells. APCs also express pattern recognition receptors (PRRs) which, when recognizing conserved microbeassociated molecular patterns, initiate signaling events that
activate APCs. Therefore, APCs act to coordinate both the innate and adaptive arms of the immune response and are pivotal in generating complete immune protection. For effective
immune protection, efficient delivery of DNA vaccines must
occur in the appropriate target tissue and to the proper cell
type. Developing strategies for controlled delivery of DNA
vaccines that preferentially home to these sites and cells is
essential for immune activation (Figure 1).
To date, three DNA vaccines have been licensed for veterinary use, and a fourth has been approved for use in pigs
used in the food supply for human consumption. All four licensed DNA vaccines are administered as an intramuscular
injection of naked pDNA,7 the simplest method of DNA vaccine delivery. While naked DNA vaccination elicited measurable levels of antigen-specific immunity when administered
intramuscularly, in most cases, the immune responses were
weak.3 Therefore, the use of biomaterials to develop delivery platforms that provide protection to pDNA and allow

for controlled, cell-targeted, and site-specific release are the
most promising strategies for improving the efficacy of DNA
vaccination strategies. The formulation of DNA vaccines into
micro- and nanoscale particles also has implications for the
immunogenicity of the delivered vaccines. Particles ranging
in size from 1 to 10 μm are the preferred platforms for targeted delivery to APCs due to their preferential uptake by
APCs over other cells, and the bulk size of microparticles
creates depots of DNA that allow for sustained exposure to
cells.16 In contrast, nanoparticles have the ability to directly
reach the lymph nodes,3 have multiple routes of uptake, and
often achieve an overall higher transfection efficiency when
compared to microparticles.17
In addition to the biomaterial delivery platform, another
consideration in DNA vaccination efficacy is the route of administration used. Delivery route can impact a vaccine’s ability to elicit the desired response by targeting various professional APCs associated with different tissues, while also
requiring different materials that adequately meet the requirements of each route of delivery. Typical routes of administration that have been investigated for DNA vaccines include parenteral routes (e.g. intramuscular, intradermal, and
subcutaneous injection) and mucosal routes (e.g. oral, intranasal, and vaginal). Delivery via the parenteral route can promote activation of tissue-specific APCs (e.g. Langerhans cells
in the dermis in intradermal injection) to induce humoral and
cellular immune responses. Recently, the mucosal route of
vaccine administration has received much attention due to
the ability to generate local immunity at body sites that serve
as common routes of entry for many pathogens.18 In particular, the oral route allows for DNA vaccine delivery to the professional APCs residing in the lamina propria underlying the
intestinal epithelium.19 Delivery via the oral route can subsequently result in both mucosal and systemic immunity due to
the highly vascularized nature of the intestinal epithelium.19
Similarly, intranasal and vaginal routes deliver DNA vaccines
to the underlying professional APCs lining the respiratory and
urogenital epithelium, which then travel to draining lymph
nodes to induce adaptive B- and T-cell immunity.20,21 This
review highlights recent attempts at improving the efficacy
of DNA vaccination though the development of novel biomaterial-based delivery platforms for use in various routes
of administration, focusing on studies ranging from 2009 to
the present, as well as focusing on parenteral administration
and mucosal administration accomplished via oral delivery.

Parenteral administration
Parental administration of DNA vaccines, including intramuscular, subcutaneous, and transdermal routes, often involves
the injection or otherwise direct administration of the delivery platform. Vaccines delivered via this route typically induce systemic immune responses including humoral and cellular responses. The following sections will discuss the use
of various biomaterial delivery systems, including synthetic
and natural polymeric systems, cationic lipid, and inorganic
particles, as well microneedle-based platforms, for parenteral administration.

Micro- and nanoparticulates for DNA vaccine delivery
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Figure 1. Micro- or nanoparticulates encapsulate plasmid DNA used for vaccine delivery. In one model, particulates can be taken up by muscle cells
or epithelial cells and pathogen-derived antigens are then transcribed and translated from plasmid DNA and secreted into extracellular spaces where
they can be taken up by B-cell receptor mediated endocytosis or by professional APCs such as macrophages or dendritic cells. (a) Alternatively, APCs
can be directly transfected by uptake of particulate encapsulated DNA. (b) Professional APCs such as macrophages are important for uptake of larger
microparticles by phagocytosis, while dendritic cells are more effective at uptake of nanoparticulates by macropinocytosis. Dendritic cells in the draining lymph nodes are especially important for presenting antigen to naïve T cells for activation and differentiation (b).

Synthetic polymers
The use of polymeric delivery systems for the delivery of
DNAs has been extensively investigated for a variety of applications including gene therapy, tissue engineering, and
DNA vaccination. Polymeric delivery systems can complex or
physically encapsulate DNA into nano- and microparticles to
provide greater protection from nucleases, allow for tunable
degradation and controlled release, and facilitate modification to achieve cell-specific targeted delivery. Perhaps, the
most widely studied polymer for DNA vaccine development is
poly(lactide-co-glycolide) (PLGA). PLGA nano- and microparticles have been used to encapsulate and deliver DNA vaccines against a variety of diseases including cancer,22 swine
influenza,23 parasitic infections,24 and hepatitis B.25 Encapsulation of DNA vaccines into PLGA in these various studies increased systemic antigen-specific antibody responses. In addition, PLGA microparticles encapsulating pDNA encoding an
antigenic protein of the human papillomavirus (HPV) have
been investigated in phase II clinical trials and were shown
to increase T-cell responses to HPV epitopes.26 Although delivery of DNA using PLGA particles has been shown to induce

immune responses, the encapsulation process can unfortunately lead to DNA degradation and ultimately lower transgene expression.
In addition to utilizing PLGA for DNA encapsulation, DNAcoated PLGA microparticles have been reported to facilitate
increased DNA loading, reduce DNA degradation throughout the formulation process, and enhance the delivery of
DNA vaccines to APCs.27 Reddy et al.28 coated cationic PLGA
microparticles with pDNA encoding the 1D gene of the foot
and mouth disease virus (FMDV) and delivered intramuscularly to guinea pigs. The DNA-coated microparticles resulted in higher FMDV-specific antibody and neutralizing antibody titers, as well as increased lymphocyte proliferation
compared to naked plasmid, for one year post vaccination
in the guinea pig model of FMDV, highlighting the ability
of microparticle-based delivery systems to induce long-lasting immune responses. While microparticles are an attractive delivery platform for DNA vaccines due to their ability
to passively target APCs based on size exclusion, the micron
size often leads to decreased transfection efficiencies. This
is particularly true for PLGA microparticles, where the large
size can lead to acidification of the microenvironment upon
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degradation of the particles, DNA degradation, and lowered
immunogenicity of vaccines. To overcome the limitation associated with PLGA microparticles, several teams have investigated PLGA nanoparticles as an alternative for DNA vaccine delivery.
Lee et al.29 developed quantum dot-loaded PLGA nanoparticles with a glycol chitosan shell for dual live cell tracking
and DNA vaccine delivery.29 The cationic glycolchitosan shell
allowed for electrostatic interaction with pDNA vaccines to
increase loading and promote pH-dependent intracellular
release. These particles were able to directly transfect Langerhans cells, tissue-specific professional APCs residing in the
dermis, with the enhanced green fluorescent reporter gene
after transdermal administration. Transgene expression in the
draining lymph nodes was increased following Langerhans
cell migration, highlighting the ability of the PLGA nanoparticles to activate APCs, and induce their migration to the draining lymph nodes, which is necessary for APC interaction with
and activation of naïve B and T cells.29 In addition to PLGA
nanoparticles, the use of other cationic polymeric materials
to form polymer/DNA nanoparticles has also been investigated for DNA vaccine delivery.
Another synthetic polymer that has been widely used in
DNA delivery, including DNA vaccines, is poly(ethylene imine) (PEI). Although the use of PEI as a non-viral gene delivery vector is well documented, PEI/DNA complexes do
suffer from toxicity issues as well as aggregation in the presence of serum proteins and rapid clearance from circulation,
which combine to limit the efficiency of DNA vaccine delivery. Therefore, Shuaibu et al.30 developed PEI/pDNA complexes coated with γ-polyglutamic acid (γ-PGA) for intravenous delivery of malaria DNA vaccine. The addition of γ-PGA
greatly reduced the surface charge of the particles, leading
to decreased aggregation and greater stability in physiological conditions. Furthermore, the addition of γ-PGA led to a
Th2-dominant immune response, which is crucial for protection against parasitic infections.31 The addition of γ-PGA was
hypothesized to act as an adjuvant by activating receptors of
the innate immune response, as γ-PGA is produced by certain strains of bacilli.32 Thus, synthetic polymers for DNA vaccine delivery are capable of inducing immunogenicity, APC
targeting, and potential PRR triggering, all of which are important for enhancing adaptive immune responses. Still, challenges remain in efficiently targeting APCs to trigger the appropriate immune responses needed for protection against
various infectious diseases. For example, the Th2 response induced by γ-PGA was protective against a parasitic infection,
but may not be effective against intracellular viral infections
that rely on CD8+ cytotoxic T cells for complete clearance.
Natural polymers
Natural materials have long been investigated for many biological applications, including tissue engineering and drug
and gene delivery, due to their inherent biocompatibility and
biodegradability. In particular, chitosan, the partially deacetylated form of chitin from crustacean and insect shells, has

been extensively investigated for DNA vaccine delivery. Due
to its positive charge, chitosan can form electrostatic interactions with the phosphate groups of DNA, condensing and
complexing it to form nanoscale complexes.33 Chitosan can
also be ionically crosslinked into nanogels containing DNA
through the use of a crosslinking anion such as sodium tripolyphosphate.34 Due to the presence of primary amines on
the polymer backbone, chitosan is well suited for a variety of
chemical modifications to increase DNA delivery such as enhanced intracellular dissociation of the DNA from the polymer35 and cell-specific targeting.36–38 Moreover, chitosan has
been shown to activate the NLRP3 inflammasome, a cytosolic
PRR of the innate immune system responsible for enhancing
proinflammatory cytokine production.39 Chitosan has been
widely used as a delivery platform for DNA vaccines for a
variety of pathogens including Leptospirosis,40 Coxsackievirus B3,41 and influenza.42,43 Chitosan nanoparticles have also
been formulated with pDNA encoding HPV-16 E7, a tumorspecific antigen for immunotherapy against HPV-associated
tumors. After intramuscular injection of the HPV-16 E7/chitosan nanoparticles, the vaccine platform induced CD8+ Tcell activation and proliferation, stimulated interferon (IFN)-γ
and interleukin (IL)-4 production, and reduced tumor size in
a mouse model.44 Similarly, chitosan nanoparticles encapsulating DNA encoding the swine flu hemagglutinin antigen resulted in robust serum IgG titers for up to eight weeks
and increased T-cell proliferation following intramuscular
immunization.45
Although chitosan-based nanoparticles show great promise as DNA vaccine delivery systems, these systems often
suffer from low transfection efficiency and subsequent low
immunogenicity. This low transfection efficiency can be attributed to poor dissociation of pDNA from chitosan in the
intracellular environment, limited stability in the presence of
serum proteins due to the highly positive charge density, and,
in the case of DNA vaccine delivery, poor cell specificity for
targeting professional APCs. To overcome these barriers and
increase the efficiency of chitosan-based delivery systems,
a variety of modification techniques have been employed.
Csaba et al.34 investigated the effects of poly(ethylene glycol)
(PEG) conjugation on particle stability and transfection efficiency. This team found that PEGylation increased the in vivo
stability of chitosan/ DNA nanoparticles due to a reduction
in surface charge and reduced interaction with serum proteins.34 The most extensively investigated functionalization
strategy for targeting chitosan to APCs is particle mannosylation to increase binding to the macrophage mannose receptor (MMR). C-type lectin receptors (such as the MMR) are
one family of PRR that contain carbohydrate-recognition domains that bind sugar moieties, including mannose. Mannose
functionalization of chitosan increases nanoparticle association with APCs and increases internalization via mannose receptor-mediated endocytosis.46–48 Layek et al.49 developed
an L-phenylalanine-modified chitosan for increased adsorptive endocytosis and intracellular dissociation of DNA, further functionalized with mannose for APC-specific targeting
(Man-CS-Phe/DNA). Following intradermal delivery of Man-
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CS-Phe/DNA complexes encoding hepatitis B surface antigen (HBsAg) to mice, high anti-HBsAg titers were observed
for up to six weeks, as well as increased lymphocyte proliferation and increased IL-4 and IFN-g production.
Both natural and synthetic polymeric delivery platforms
serve to increase immune activation in response to DNA vaccines through increased APC targeting and uptake. Despite
increases in the immunogenicity of DNA vaccines due, in part,
to targeting strategies and carrier modifications, there still remains challenges in achieving the appropriate immune response, specifically balanced Th1 and Th2 helper T-cell differentiation to drive both T cell and antibody- based immunity.
In addition to synthetic and natural polymeric DNA vaccine
delivery platforms, non-polymeric delivery systems, including
cationic lipid and inorganic particulates also hold potential for
increasing the efficiency of DNA-based immune responses.
Cationic lipids and inorganic nanoparticles
Cationic lipids have been widely used as non-viral gene delivery platforms since first introduced by Felgner et al.50 The
amphiphilic nature of cationic lipids allows for self-assembly
into lipoplexes and liposomes. The use of cationic lipids for
the delivery of DNA vaccines in particular has received much
interest due to their abilities to control liposome size, functionalize the carrier, and activate innate immune receptors
such as PRR.51 Moreover, novel synthesis techniques for lipidbased systems allow for APC targeting of lipoplex and liposome DNA vaccine delivery platforms. Srinivas et al.52 developed cationic amphiphiles containing mannose-mimicking
shikimic acid head groups to enhance the delivery of DNA
vaccines to professional APCs via targeting of the MMR. The
lipoplexes were able to mediate transgene expression in an
MMR-dependent manner in a macrophage cell line and were
also shown to transfect bone marrow-derived DCs. Furthermore, this delivery system was employed to deliver melanoma tumor-associated antigen and resulted in long-lasting
protective immunity in mice.52 Similarly, Perche et al.53 developed a mannose-functionalized lipopolyplex delivery system
to deliver antimelanoma antigen mRNA. The platform consisted of PEGylated, histidylated polylysine/mRNA complexes
further encapsulated in mannosylated liposomes. The functionalized lipopolyplexes led to increased specific internalization into DCs and suppressed tumor growth in vaccinated
mice due to the pH-sensitive destabilization of endosomal
membranes and cytosolic release of the mRNA vaccine.53
Such RNA vaccines represent a promising approach to vaccination, as the mRNA payload can be translated into the antigenic protein of interest within the cytosol. Importantly, this
approach eliminates the need for nuclear import, which has
been established as a major intracellular barrier to successful gene delivery. The development of biomaterials able to
protect RNA, which is highly susceptible to enzymatic degradation, and target its delivery to APCs will be instrumental
to successful immune protection.
In addition to polymers and lipids, hybrid particles consisting of inorganics combined with polymers have also been
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investigated for DNA vaccination delivery strategies. Ye et al.
developed iron oxide nanoparticles coated with γ-glutamic
acid and PEI for the delivery of pDNA encoding both IL-21
and Mycobacterium tuberculosis (MTb) antigen for inducing
protective immunity in mice. Intramuscular immunization
with these nanoparticles resulted in co-expression of immunostimulatory IL-21 and target antigen, leading to increased
activation of T lymphocytes, and subsequent protection following MTb challenge. Wang et al.54 developed core-shell
silicon oxide-layered double hydroxides (SiO2 LDH), encapsulating pDNA encoding HBsAg. The SiO2 LDH/DNA nanocomposites were effectively internalized by macrophages,
leading to high reporter gene expression in vitro. Upon parenteral administration to mice, the SiO2LDH/pHBsAg leads
to enhanced HBV antibodies and antigen-specific T-cell responses. Moreover, vaccination with the SiO2LDH/pHBVsAg
nanoparticles activated macrophages and promoted Th1 differentiation via activation of the NF-κB pathway. LDH-DNA
particulates have also been investigated for enhancing the
efficacy of melanoma tumor vaccines. Subcutaneous injection of the LDH-DNA particles led to increased antigen-specific Ig titers and significantly reduced tumor growth.55 In the
case of tumor vaccine therapies, activated cytolytic CD8+
T cells are the main effector cells responsible for eliminating tumor cells; therefore, it is crucial to generate a type 1
immune response for cytotoxic T-cell differentiation. Biomaterial-based DNA vaccine delivery systems allow for the
targeted delivery of immunostimulatory cytokines (such as
IL-12), either through encapsulation within the biomaterial
matrix or via coexpression of an antigen/cytokine dual plasmid. The targeted delivery of such stimulatory molecules
along with a specific antigen would be capable of inducing
strong immune responses, while also limiting the negative
effects often seen with systemic circulation of immunostimulatory cytokines.
Recently, the use of cationic solid lipid nanoparticles
(cSLN) has been investigated for gene delivery applications
due to their ability to increase DNA stability and loading as
well as overcome some of toxicity concerns that are associated with lipoplex delivery systems. Doroud et al.56 developed cSLN containing a cocktail of DNA vaccines against
Leishmania major, a protozoan parasite responsible for cutaneous leishmaniasis. These cSLN represent a unique delivery system for enhancing the immune response due to
the presence of 1,2-dioleoyl-3-trimethylammonium-propane, a cationic surface-active lipid that has been shown to
activate DCs and drive their maturation through binding of
PRR,57 highlighting the adjuvant activity of some lipid delivery
platforms. Upon subcutaneous footpad injection in mice, the
cSLN delivery system was able to reduce the parasitic burden in lymph nodes and induce high levels of IFN-γ and IL5, indicators of Th1 and Th2 immune responses, respectively.
The above studies highlight the use of micro- and nanoparticles consisting of polymeric and non-polymeric materials
that often require direct injection to activate an immune response, therefore requiring administration from medically
trained personnel. Consequently, patient compliance is com-
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Figure 2. Cross-sectional representation of the intestinal epithelium and underlying immune cells of the Lamina Propria. DNA encapsulated microand nanoparticulates delivered via the oral route can take advantage of multiple routes to transfect cells or APCs for antigen expression and immune
activation. (a) Nanoparticles can be directly sampled from the intestinal lumen to transfect DCs. (b) DNA vaccine-loaded particulates can be taken up
by intestinal epithelial cells which then produce and secrete the desired antigen for sampling by professional APCs. (c) DNA vaccine-loaded particulates can undergo transcytosis across the intestinal epithelium by specialized M cells where they may transfect cells of the mucosa-associated lymphoid tissue (specifically Peyer’s Patches).

promised, and widespread, rapid deployment of DNA-based
vaccines, especially to resource poor environments, is crippled. To truly appreciate the translational potential of such
systems, biomaterial-based delivery platforms must facilitate
patient compliance and utilize delivery routes conducive to
simple administration. One promising alternative to direct
injection that still makes use of the parenteral route is the
use of transdermal microneedle patches, which can also improve both patient compliance and the immunogenicity of
DNA vaccines.58–60
Microneedles
Delivery of vaccines transdermally has shown to increase vaccine immunogenicity, as well as serve a simple and safe delivery strategy.61 Microneedles consist of solid micron-scale
needles that can be composed of biodegradable materials
(e.g. PLGA, chitosan or polylactic acid) for sustained release
of vaccines as well as non-degradable materials (e.g. stainless steel)62 that serve to penetrate the epidermis of the skin
to deliver DNA vaccines to the resident APCs within the dermis, the Langerhans cells. Hu et al.63 developed mannosylated
cell-penetrating peptide-conjugated PEI/DNA complexes encoding tumor antigen delivered via microneedles. The transdermal delivery system was able to efficiently target skin DCs
and induce strong Th1 differentiation and CD4+ and CD8+
cell infiltration into solid tumors. Moreover, microneedles
present an ideal substrate for the use of polyelectrolyte multilayers to co-deliver DNA vaccines along with adjuvant materials. DeMuth et al.64 developed poly(L-lactide) microneedles coated with alternating layers of pDNA/polyI:C adjuvant

and biodegradable poly(β-amino-ester) (PBAE). The coated
microneedles were able to sustain the release of pDNA and
PBAE to form in situ polyplexes and mediate robust immune
responses against a model HIV antigen. Microneedle arrays
have also been coated with virus-like particles (VLP) encapsulating HPV antigen. VLPs are nonreplicating molecules that
consist of an empty particle that has a structure similar to
that of pathogenic viruses. The VLP vaccine-coated stainless
steel microneedles elicited strong neutralizing antibodies as
well as CD4+ and CD8+ T-cell activation upon transdermal
administration.60 All of the above studies indicate the potential of parenterally administration of DNA vaccines to generate effective humoral and cellular-mediated immune responses; however, these routes of administration typically do
not result in the generation of mucosal immunity, which will
be discussed in the next section.

Mucosal administration: Oral delivery
Mucosal immunity is considered an important first line of
defense against many pathogens; consequently, vaccines
that generate both systemic and mucosal immunity are of
great interest. DNA vaccines delivered via mucosal routes
(i.e. oral, intranasal, and vaginal) offer the advantages of
high patient compliance and the ability to generate both
mucosal and systemic immunity. However, delivery via mucosal routes introduces additional challenges to the successful delivery of DNA vaccines and subsequent activation
the immune system. Specifically, the delivery vehicle must
penetrate the mucous layer and be transported across the
epithelial layer while still specifically targeting the under-
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lying APCs (Figure 2). The following sections discuss approaches in developing biomaterial-based DNA vaccine delivery systems that address some of these obstacles and also
highlight challenges that must be overcome for successful
mucosal administration.
Inorganic particles, liposomes and virus-like particles
Of all the possible routes for vaccine administration, the oral
route is often considered preferable due to patient compliance given the ease of administrating and dosing without
medically trained personnel.19,65 For oral delivery of DNA vaccines, the intestinal epithelium represents a unique target due
to its large cellular surface area, highly vascularized nature,
and ability to generate mucosal immunity. One constituent of
the intestinal mucosa, the lamina propria, is rich in APCs, including macrophages and DC, which are able to sample antigens directly from the intestinal lumen as well as antigens
that have been transported across the intestinal epithelium.66
These APCs are instrumental in generating B-cell and T-cell
responses and providing protection against pathogens that
enter via mucosal sites.67 Moreover, due to the highly vascularized nature of the intestinal epithelium, oral DNA vaccines
also have the potential to generate systemic immunity in addition to mucosal immunity.68 Oral delivery of DNA vaccines
has been an area of interest for multiple research groups but
has only seen limited success, mainly due to the degradation of DNA by endogenous nucleases and the harsh conditions encountered in the gastric environment.66 Additionally, the mucosal epithelium presents additional challenges
such as a highly viscous mucus layer and specialized enzymatic processes that only specific biomaterials may be able
to overcome.
The use of liposomes for oral DNA vaccine delivery has
been well documented. Wang et al.69 developed liposomal
systems for delivery of DNA encoding MTb antigen and oral
administration which generated antigen-specific mucosal
and systemic humoral immunity against tuberculosis. Moreover, this platform produced efficient antigen expression by
Microfold (M) cells, which are implicated in transporting antigen across the intestinal epithelium for sampling by professional APCs. In addition to traditional liposomes, nonionic surfactant-based vesicles (niosomes) have also been
reported to possess strong adjuvant properties. Jain et al.70
produced mannosylated niosomes encapsulating pDNA encoding HBsAg for oral mucosal vaccination. The mannan
coating stabilized the niosomes throughout the gastrointestinal (GI) tract and targeted the mannose receptor present on APCs. Oral vaccination of mice with the modified
niosomes induced strong cellular and humoral immune responses, while also inducing the production of neutralizing secretory IgA, a key antibody produced during mucosal
immune responses. While lipid-based systems can deliver
DNA vaccines via the oral route, these platforms have limited stability in the GI tract and often undergo degradation
due to enzymes and the presence of bile salts that serve to
solubilize the lipids.
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Synthetic and natural polymers
While the previous studies have described the use of lipid
based systems for oral delivery, the most studied delivery
platforms for oral vaccination consist of synthetic and natural polymer platforms due to their highly tunable nature and
ability to be modified for enhanced biodegradability, 71,72
controlled release,73 and cellular targeting.74–76 As previously
mentioned, the natural polymer chitosan has been extensively investigated for the delivery of DNA vaccines via intramuscular and peritoneal routes, but chitosan is also uniquely
suited for mucosal delivery applications. Chitosan delivery
systems have characteristics that make them an ideal choice
for oral DNA delivery, including good biocompatibility and
biodegradability, high affinity for DNA, and mucoadhesive
properties,77,78 which allow an increased residence time in
the intestinal mucosa and increased sampling by APCs in the
underlying lamina propria. In addition, targeting of APCs is
possible with ligand modification of the chitosan polymer.79,80
While chitosan nanoparticles have been used orally to deliver
DNA vaccines, including successes against Toxoplasma gondii,67 Schistosoma mansoni,81 and Coxsackie B virus-induced
myocarditis,82 the amount of transgene/antigen production
can be low due to chitosan instability in the acidic gastric environment and DNA degradation by digestive enzymes. While
these synthetic and natural polymeric delivery vehicles hold
great promise for oral DNA vaccine delivery, the instability
of many polymeric systems in the GI tract, coupled with the
variability in the GI environments, emphasize the need for the
development of hybrid delivery platforms that protect DNA
vaccines through complete GI transit.
Hybrid particles
The use of multiple materials for developing oral delivery
systems is considered an attractive strategy for overcoming the challenges of complete DNA protection through GI
tract transit, as well as the controlled delivery and targeting of the cargo to APCs in the lamina propria of the intestinal epithelium. Dual material systems offer the advantage
of selecting properties to match the requirements of each
compartment of the GI tract, including protection from gastric conditions and subsequent release in the intestinal environment. Materials that can serve as a protective coating or
form an encapsulating matrix around DNA complexes are of
special interest. Bhavsar et al.83 developed an oral gene delivery platform consisting of gelatin/DNA nanoparticles encapsulated in poly(ε-caprolactone) (PCL) microspheres. Encapsulation of the gelatin particles in the PCL matrix provided
protection of the DNA from the gastric environment and increased the delivery of intact gelatin/DNA nanoparticles in
the intestine.83 However, the slow and potentially toxic degradation of PCL and the use of harsh particle formulation methods can lead to undesired DNA release kinetics, toxicity, and
DNA degradation during processing. To overcome some of
these limitations, Bhowmik et al.84 developed a composite microparticle delivery platform consisting of synthetic and nat-
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ural polymers for the oral delivery of pDNA encoding HBsAg.
The microparticles, containing chitosan as well as consisting
of equal ratios of albumin, hydroxyproplymethylcellulose acetate succinate, and eudragrit, were formed via a spray drying
method. The combination of polymers served to enhance the
oral stability of the microparticles, as well as impart mucoadhesive properties to enhance delivery to cells in the intestinal epithelium. The microparticles were further functionalized with the M-cell targeting ligand Aleuria Aurantia Lectin
to enhance targeted delivery to APCs. Oral administration
of the microparticles led to increased serum IgG and fecal
IgA titers when compared to subcutaneous injection, indicating the induction of both systemic and mucosal immune
responses. Similarly, Channarong et al.85 investigated chitosan/DNA-loaded liposomes, further modified with a chitosan
coating, for improving targeting to Peyer’s patches. Chitosan/DNA complexes were entrapped in liposomes consisting of phosphatidylcholine and cholesterol using a thin film
fabrication method. The chitosan coating increased the protective abilities of the chitosan/DNA-loaded liposomes and
resulted in stable lipopolyplexes in both gastric and intestinal fluid. In vivo studies with orally delivered chitosan/DNAloaded liposomes indicated transgene expression throughout the upper and lower intestine, an observation attributed
to the bioadhesive nature of chitosan, which allows for increased residence time in the intestine.
While these synthetic and lipid-based platforms highlight
the advantages of using several materials in designing oral
delivery systems, issues with toxicity and complete protection remain. Consequently, there is increasing interest in designing systems that make use of only natural materials and
processing conditions that do not affect DNA integrity. Recently, Liu et al.86 developed an oral delivery system consisting of alginate-coated chitosan/DNA nanoparticles to provide protection against breast cancer metastasis. The coating
of alginate, a natural polymer derived from brown seaweed,
provided protection to the chitosan/DNA nanoparticles in
low pH conditions (i.e. gastric) and were taken up by macrophages and DCs in the intestinal Peyer’s patches upon oral
administration to mice.86 Furthermore, this vaccination strategy inhibited tumor growth and increased survival in an orthotopic 4T1 breast cancer model.
Another natural biomaterial that has recently gained interest for gene delivery applications is zein. Zein is the major prolamine, or storage protein, from corn comprising 45–
60% of the total corn protein. The presence of polar and
non-polar amino acids allows zein molecules to self-assemble into a variety of structures including nano- and microparticles as well as uniform films87–89 and allows zein to interact
with and encapsulate a variety of hydrophobic and hydrophilic compounds including vitamins,90 essential oils,91 antiparasitic drugs92 and in our previous work, DNA.93 Due to
its inherent biocompatibility and biodegradability as well as
its ability to self-assemble to form particles and coatings,
zein has already been employed in pharmaceutical tableting, specifically for oral delivery applications. Recently, our
group has developed an oral delivery system consisting of

zein microparticles encapsulating chitosan/DNA nanoparticle cores for enhanced delivery of DNA vaccines to APCs in
the intestinal lamina propria. The zein microparticles, due to
their resistance to aqueous acidic environments and gastric
enzymes, were used to encapsulate and protect the chitosan/
DNA nanoparticles from dissolution and degradation in the
gastric environment (data not shown). These particles demonstrate that future design of biomaterials for oral DNA vaccine delivery will require much consideration for the various
requirements of the different GI tract compartments.

Conclusions
Vaccination has led to great improvements in overall world
health and has served to greatly reduce the prevalence of
infectious diseases. However, vaccines for rapidly mutating
and emerging diseases often fail to elicit complete protective
immune responses. DNA-based vaccine strategies present
several advantages over traditional protein-based vaccines.
First, DNA vaccines result in the intracellular production of
the target antigen and subsequent presentation to the immune system. In turn, a more balanced T-and B-cell response
is generated, which ultimately gives rise to populations of
resident memory T cells important in fighting mutating viral infections. Second, DNA vaccines allow for rapid, largescale production of antigen-specific vaccines and eliminate
the need for cold chain storage and transportation, making
them suited for rapidly emerging, pandemic diseases.
In order to realize the great potential of DNA vaccines
and produce clinically relevant vaccine strategies, there remains the need for development of proper delivery platforms
combined with appropriate delivery routes that achieve efficient transfection of immune cells. Biomaterial-based delivery systems based on micro- and nanoparticles that encapsulate and protect DNA vaccines represent the most promising
strategy for DNA vaccination. Microparticulate delivery systems allow for passive targeting to APCs through size exclusion and can promote sustained presentation of DNA to
cells through degradation and release of encapsulated vaccines. Nanoparticles offer increased internalization, overall
greater transfection efficiency, and the ability to increase uptake across mucosal surfaces. Moreover, selection of the appropriate biomaterial can lead to increased immune stimulation and activation by triggering innate immune response
receptors. Finally, selecting materials with the appropriate
properties to achieve efficient delivery via administration
routes that are not only conducive to high patient compliance but also generate systemic and local, mucosal immunity can lead to more effective protective humoral and cellular immune responses. With continued material development
to increase delivery efficiency and immunogenicity, DNA vaccines will offer a promising alternative to traditional vaccination strategies.
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